

NTCELL Clinical Study results to be announced on Friday 10 November

Results of NTCELL® Clinical Study in Parkinson's

- Results released to ASX on Friday 10 November
- Company to host conference call on Friday 10 November at 2:00pm AEST / 4:00pm NZT

LCT has announced a trading halt ahead of the announcement of the results of the Phase IIb clinical study of NTCELL in Parkinson's disease on Friday 10 November.

Investor call

LCT CEO Ken Taylor and Principal Investigator Dr Barry Snow will host an investor call to discuss the results of the Phase IIb clinical study of NTCELL in Parkinson's disease on the day of the announcement.

Date: Friday 10 November 2017

Time: NZT 4:00pm, AEST 2:00pm

Conference ID: 3389168

Toll-free dial-in numbers for participants:

Australia - 1800 123 296

New Zealand - 0800 452 782

Canada - 1855 5616 766

China - 4001 203 085

Hong - Kong 800 908 865

India - 1800 3010 6141

Japan - 0120 985 190

Singapore - 800 616 2288

United Kingdom - 0808 234 0757

United States - 1855 293 1544

or

toll +61 2 8038 5221